Share

Oxygenta Pharmaceutical Limited Stocks

52.74Last Updated 16.02.2026

Issuer Rating

3/7

Performance

Average

Risk

High

Recommendation

Sell

Market Cap

₹ 19.33M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
52.74
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Oxygenta Pharmaceutical Ltd. engages in the development and manufacture of bulk drugs. It offers anti-ulcerative and anti-bacterial drugs. The company was founded on November 27, 1990 and is headquartered in Hyderabad, India.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks